Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa.
Jolynne MokayaEdward A O BurnCynthia Raissa TamandjouDominique GoedhalsEleanor J BarnesMonique AnderssonRafael Pinedo-VillanuevaPhilippa Clare MatthewsPublished in: BMC public health (2019)
Given the long-term health burden for individuals and economic burden for society associated with chronic HBV infection, screening pregnant women and providing tenofovir for all who test HBsAg+ may be a cost-effective strategy for South Africa and other low/middle income settings.